L A Mitchell

Summary

Affiliation: University of British Columbia
Country: Canada

Publications

  1. ncbi Rubella virus vaccine associated arthropathy in postpartum immunized women: influence of preimmunization serologic status on development of joint manifestations
    L A Mitchell
    Department of Pathology, Faculty of Medicine, University of British Columbia, Vancouver, Canada
    J Rheumatol 27:418-23. 2000
  2. ncbi Characterization of rubella virus-specific antibody responses by using a new synthetic peptide-based enzyme-linked immunosorbent assay
    L A Mitchell
    Department of Pathology, Faculty of Medicine, University of British Columbia, Vancouver, Canada
    J Clin Microbiol 30:1841-7. 1992
  3. ncbi Serologic responses to measles, mumps, and rubella (MMR) vaccine in healthy infants: failure to respond to measles and mumps components may influence decisions on timing of the second dose of MMR
    L A Mitchell
    Department of Pathology, University of British Columbia, BC Research Institute for Children s and Women s Health, Vancouver
    Can J Public Health 89:325-8. 1998
  4. ncbi Rubella reimmunization: comparative analysis of the immunoglobulin G response to rubella virus vaccine in previously seronegative and seropositive individuals
    L A Mitchell
    Department of Pathology, University of British Columbia, Vancouver, Canada
    J Clin Microbiol 34:2210-8. 1996
  5. ncbi Sex differences in antibody- and cell-mediated immune response to rubella re-immunisation
    L A Mitchell
    Department of Pathology, University of British Columbia, Vancouver, Canada
    J Med Microbiol 48:1075-80. 1999
  6. ncbi New, ultrasensitive enzyme immunoassay for detecting vaccine- and disease-induced hepatitis A virus-specific immunoglobulin G in saliva
    J J Ochnio
    Vaccine Evaluation Center, BC s Children s Hospital, Vancouver, Canada
    J Clin Microbiol 35:98-101. 1997
  7. ncbi HLA-DR class II associations with rubella vaccine-induced joint manifestations
    L A Mitchell
    Department of Pathology, University of British Columbia, Vancouver, Canada
    J Infect Dis 177:5-12. 1998
  8. ncbi Identification of rubella virus T-cell epitopes recognized in anamnestic response to RA27/3 vaccine: associations with boost in neutralizing antibody titer
    L A Mitchell
    Department of Pathology, University of British Columbia, Vancouver, Canada
    Vaccine 17:2356-65. 1999

Detail Information

Publications8

  1. ncbi Rubella virus vaccine associated arthropathy in postpartum immunized women: influence of preimmunization serologic status on development of joint manifestations
    L A Mitchell
    Department of Pathology, Faculty of Medicine, University of British Columbia, Vancouver, Canada
    J Rheumatol 27:418-23. 2000
    ..To measure preimmunization rubella virus (RV)-specific IgG levels and to relate these to the development of acute and chronic (persistent or recurrent) joint manifestations following rubella vaccination...
  2. ncbi Characterization of rubella virus-specific antibody responses by using a new synthetic peptide-based enzyme-linked immunosorbent assay
    L A Mitchell
    Department of Pathology, Faculty of Medicine, University of British Columbia, Vancouver, Canada
    J Clin Microbiol 30:1841-7. 1992
    ..Our results that the sequence represented by BCH-178 peptide may be a previously unidentified neutralization epitope for human antibodies on the RV E1 protein and may prove useful in determining effective RV immunity...
  3. ncbi Serologic responses to measles, mumps, and rubella (MMR) vaccine in healthy infants: failure to respond to measles and mumps components may influence decisions on timing of the second dose of MMR
    L A Mitchell
    Department of Pathology, University of British Columbia, BC Research Institute for Children s and Women s Health, Vancouver
    Can J Public Health 89:325-8. 1998
    ..These observations suggest that earlier administration (at age 18 months) of the second dose of MMR may be more desirable than revaccination at school entry...
  4. ncbi Rubella reimmunization: comparative analysis of the immunoglobulin G response to rubella virus vaccine in previously seronegative and seropositive individuals
    L A Mitchell
    Department of Pathology, University of British Columbia, Vancouver, Canada
    J Clin Microbiol 34:2210-8. 1996
    ....
  5. ncbi Sex differences in antibody- and cell-mediated immune response to rubella re-immunisation
    L A Mitchell
    Department of Pathology, University of British Columbia, Vancouver, Canada
    J Med Microbiol 48:1075-80. 1999
    ....
  6. ncbi New, ultrasensitive enzyme immunoassay for detecting vaccine- and disease-induced hepatitis A virus-specific immunoglobulin G in saliva
    J J Ochnio
    Vaccine Evaluation Center, BC s Children s Hospital, Vancouver, Canada
    J Clin Microbiol 35:98-101. 1997
    ..We conclude that this assay is sufficiently sensitive for reliable detection of both vaccine- and infection-induced HAV-specific immunoglobulin G in saliva, even when corresponding anti-HAV levels in serum are very low (< 1 IU/ml)...
  7. ncbi HLA-DR class II associations with rubella vaccine-induced joint manifestations
    L A Mitchell
    Department of Pathology, University of British Columbia, Vancouver, Canada
    J Infect Dis 177:5-12. 1998
    ..45-44.02) and 7.1 times greater with both DR4 and DR6 present (95% CI, 1.85-27.52), suggesting that coexpression of these specificities may predispose to postpartum arthropathy...
  8. ncbi Identification of rubella virus T-cell epitopes recognized in anamnestic response to RA27/3 vaccine: associations with boost in neutralizing antibody titer
    L A Mitchell
    Department of Pathology, University of British Columbia, Vancouver, Canada
    Vaccine 17:2356-65. 1999
    ....